

The global pharma industry is on a growth trajectory yet must overcome challenges to capture value in a changing environment. Agility and more sophisticated commercialisation capability is required to address portfolio shifts, new economics, and expectations on the industry.
This white paper explores key drivers to re-imagine commercialisation and outlines steps pharmaceutical companies can take now to build winning strategies and leadership capabilities allowing to realise growth.
Why innovators should take heart from recent advances seen in obesity and beyond
Achieving commercial launch excellence for the most innovative medicines in areas of high unmet need
How to deliver consistent launch performance in an increasingly complex world
How to navigate harsh realities in a highly fluid environment
Deep dive: Antibody drug conjugates, bi-/multi-specifics and radioligand therapies